Monotherapy dose escalation of davoceticept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1)

Michael Millward; Justin C. Moser; Diwakar Davar; Mark Voskoboynik; Nehal J. Lakhani; Rachel E. Sanborn; Jaspreet Grewal; Ajita Narayan; Mario Sznol; Keren Schieber; Hany Zayed; Christine Dela Cruz; Graciela Perez; Stanford L. Peng

doi:10.1158/1538-7445.AM2022-CT041

Monotherapy dose escalation of davoceticept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1)

Michael Millward, Justin C. Moser, Diwakar Davar, Mark Voskoboynik, Nehal J. Lakhani, Rachel E. Sanborn, Jaspreet Grewal, Ajita Narayan, Mario Sznol, Keren Schieber, Hany Zayed, Christine Dela Cruz, Graciela Perez, Stanford L. Peng

Internal Medicine

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

1 Citation (Web of Science)

Original language	English
Number of pages	2
Journal	Cancer Research
Volume	82
Issue number	12
DOIs	https://doi.org/10.1158/1538-7445.AM2022-CT041
Publication status	Published - 15 Jun 2022
Event	113th Annual Meeting of the American-Association-for-Cancer-Research - New Orleans, United States Duration: 8 Apr 2022 → 13 Apr 2022

Access to Document

10.1158/1538-7445.AM2022-CT041Licence: Unspecified

Cite this

Millward, M., Moser, J. C., Davar, D., Voskoboynik, M., Lakhani, N. J., Sanborn, R. E., Grewal, J., Narayan, A., Sznol, M., Schieber, K., Zayed, H., Dela Cruz, C., Perez, G., & Peng, S. L. (2022). Monotherapy dose escalation of davoceticept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1). Cancer Research, 82(12). https://doi.org/10.1158/1538-7445.AM2022-CT041

@article{b9b9ec1f21804c948e25d2222e695ace,

title = "Monotherapy dose escalation of davoceticept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1)",

author = "Michael Millward and Moser, {Justin C.} and Diwakar Davar and Mark Voskoboynik and Lakhani, {Nehal J.} and Sanborn, {Rachel E.} and Jaspreet Grewal and Ajita Narayan and Mario Sznol and Keren Schieber and Hany Zayed and {Dela Cruz}, Christine and Graciela Perez and Peng, {Stanford L.}",

year = "2022",

month = jun,

day = "15",

doi = "10.1158/1538-7445.AM2022-CT041",

language = "English",

volume = "82",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research (AACR)",

number = "12",

note = "113th Annual Meeting of the American-Association-for-Cancer-Research , AACR ; Conference date: 08-04-2022 Through 13-04-2022",

}

Millward, M, Moser, JC, Davar, D, Voskoboynik, M, Lakhani, NJ, Sanborn, RE, Grewal, J, Narayan, A, Sznol, M, Schieber, K, Zayed, H, Dela Cruz, C, Perez, G & Peng, SL 2022, 'Monotherapy dose escalation of davoceticept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1)', Cancer Research, vol. 82, no. 12. https://doi.org/10.1158/1538-7445.AM2022-CT041

TY - JOUR

T1 - Monotherapy dose escalation of davoceticept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1)

AU - Millward, Michael

AU - Moser, Justin C.

AU - Davar, Diwakar

AU - Voskoboynik, Mark

AU - Lakhani, Nehal J.

AU - Sanborn, Rachel E.

AU - Grewal, Jaspreet

AU - Narayan, Ajita

AU - Sznol, Mario

AU - Schieber, Keren

AU - Zayed, Hany

AU - Dela Cruz, Christine

AU - Perez, Graciela

AU - Peng, Stanford L.

PY - 2022/6/15

Y1 - 2022/6/15

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=uwapure5-25&SrcAuth=WosAPI&KeyUT=WOS:000892509502093&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1158/1538-7445.AM2022-CT041

DO - 10.1158/1538-7445.AM2022-CT041

M3 - Abstract/Meeting Abstract

SN - 0008-5472

VL - 82

JO - Cancer Research

JF - Cancer Research

IS - 12

T2 - 113th Annual Meeting of the American-Association-for-Cancer-Research

Y2 - 8 April 2022 through 13 April 2022

ER -

Monotherapy dose escalation of davoceticept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1)

Access to Document

Other files and links

Cite this